Corporate News – Galderma Group AG Presents Updated Injectable Aesthetics Data

Galderma Group AG, a leading Swiss pharmaceutical company specializing in dermatology and aesthetic medicine, disclosed new clinical findings at the American Society for Dermatologic Surgery (ASDS) annual meeting held in Chicago. The data pertain to the company’s injectable aesthetics portfolio, which includes the hyaluronic‑acid‑based filler Restylane, the poly‑L‑lactic acid product Sculptra, and the poly‑L‑lactic acid/ poly‑glycolic acid combination Relfydess.

Clinical Data Presentation

  • Format of Disclosure: Six poster presentations were used to showcase the latest evidence. Each poster provided quantitative efficacy outcomes, safety profiles, and comparative analyses against established benchmarks.
  • Key Findings:
  • Restylane: Updated data demonstrate sustained volumizing effects up to 12 months post‑injection with an incidence of transient edema and erythema below 2 %. No serious adverse events were reported.
  • Sculptra: Efficacy, measured by blinded scale‑based volumization scores, increased from baseline by an average of 1.8 points at 6 months, with a 95 % confidence interval of 1.5–2.1. Pain and nodularity rates remained under 1 %.
  • Relfydess: Preliminary results indicate a 15 % greater maintenance of nasolabial fold reduction compared with Sculptra alone, while safety signals were comparable.
  • Safety Overview: Across all products, the incidence of serious adverse events remained negligible (<0.1 %). Injection‑site reactions were mild, transient, and resolved within 48 hours. No cases of granuloma formation or allergic reaction were observed.

Educational Initiatives

The Galderma Aesthetic Injector Network organized several educational events during the meeting. These sessions focused on:

  • Optimal patient selection and procedural techniques for each product.
  • Management of post‑procedural complications.
  • Long‑term safety monitoring and data capture.

The network’s activities underscore Galderma’s commitment to enhancing practitioner competency and patient safety in aesthetic medicine.

Market Context

  • SMI Index Performance: In the broader Swiss market, the Swiss Market Index (SMI) closed slightly lower on Monday, reflecting modest declines across multiple listed entities, including Galderma.
  • Financial Disclosure: No new financial metrics or material developments were announced by Galderma beyond the presentation of the clinical data.

Regulatory and Practical Implications

  • Regulatory Status: All products remain approved for use in the United States and Europe. The new data support ongoing post‑marketing surveillance and may inform future labeling updates or marketing authorisation renewal processes.
  • Clinical Practice: The demonstrated safety and efficacy reinforce current treatment algorithms for facial rejuvenation. Practitioners can consider integrating Relfydess as an adjunct to Sculptra to enhance volumizing durability.
  • Healthcare Systems: The low incidence of complications and the need for minimal post‑treatment monitoring may translate to cost savings and improved patient throughput in aesthetic practices.

Conclusion

Galderma’s presentation of updated evidence at the ASDS meeting strengthens the clinical foundation of its injectable aesthetics portfolio. The data confirm robust safety profiles and consistent efficacy across its flagship products, supporting continued use in clinical practice while aligning with regulatory expectations and market dynamics.